Immunotherapeutic strategy in the management of gastric cancer: molecular profiles, current practice, and ongoing trials

Gastric cancer (GC) is the one of the most commonly solid cancer worldwide. Although under the aggressive treatment, the poor clinical outcomes of patients with GCs have not been improved. Current studies emphasized that targeting therapies or immune response-based therapeutic strategy may be a pote...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Egyptian National Cancer Institute 2023-12, Vol.35 (1), p.32-12
Main Authors: Lu, Mengxiao, Wu, Yingjie, Zhang, Yixin, Yu, Yu, Wang, ShengJie, Su, Xiaobao
Format: Article
Language:English
Subjects:
B cells
Biomarkers
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Clinical outcomes
Cytotoxicity
Epstein-Barr virus
Gastric cancer
Health aspects
Immune checkpoint inhibitors
Immune response
Immunotherapy
Infections
Ipilimumab
Kinases
Lymphocytes
Medical prognosis
Metastasis
PD-L1
Prognosis
Stomach cancer
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gastric cancer (GC) is the one of the most commonly solid cancer worldwide. Although under the aggressive treatment, the poor clinical outcomes of patients with GCs have not been improved. Current studies emphasized that targeting therapies or immune response-based therapeutic strategy may be a potential approach to improve the clinical outcomes. Moreover, accumulative evidence has reported the increasing expression of PD-L1 expression in GC cells and highlighted its role in the tumor progression. Currently, great development has been established in the immune checkpoint inhibitors (ICIs) and further changed the clinical practice of GC treatment and prognosis. In addition, the combination therapies with targeting therapy or traditional therapies are expected to push the development of immunotherapies. In our present review, we predominantly focus on the biomarkers and molecular profiles for immunotherapies in GCs and highlight the role and administration of ICIs-based immunotherapeutic strategies against the GCs.
ISSN:1110-0362
2589-0409
DOI:10.1186/s43046-023-00192-1